Longer survival in patients with NSCLC thanks to the combination of chemotherapy, immunotherapy and targeted therapy in the first line palliative treatment - results of the IMpower150 study
Abstract
In recent years, great progress has been made in the treatment of lung cancer, which was largely given by the use of immunotherapy. Nowadays, the survival of patients with generalized non-small cell lung cancer (NSCLC) is not just a few months anymore.
This has been evidenced also by the IMpower150 study, in which atezolizumab was added to bevacizumab and chemotherapy in patients with metastatic non-squamous NSCLC. The main idea was to hypothesize that VEGF blockade would lead to greater efficacy of immunotherapy in patients with non-squamous NSCLC.
Results of the study showed a significant prolongation of progression-free survival as well as overall survival. Higher efficacy was observed in the group of patients with high PD-L1 expression, however even in patients with low expression, there was a noticeable therapeutic benefit, as well as in the subgroup of patients with liver metastases or in patients with EGFR or ALK mutations.